Abstract: Point-of-care testing (POCT) is changing the way diagnostic information is generated, interpreted, and used. Its value extends well beyond shortening turnaround time. A meaningful POCT result should support a defined clinical or public-health action, such as early triage, treatment selection, disease surveillance, referral, or longitudinal follow-up. In this sense, POCT is best understood as a distributed extension of laboratory medicine rather than a simplified replacement for the central laboratory (Banfi et al., 2024; Plebani et al., 2025).

[1]AtesHC, NguyenPQ, Gonzalez-MaciaL, et al., 2022. End-to-end design of wearable sensors. Nat Rev Mater, 7(11):887-907.

[2]BanfiG, BožičB, CihanM, et al., 2024. Point-of-care testing, near-patient testing and patient self-testing: warning points. Clin Chem Lab Med, 62(12):2388-2392.

[3]ChenJS, MaE, HarringtonLB, et al., 2018. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science, 360(6387):436-439.

[4]DingS, LiJ, YangML, et al., 2026. DNA-based one-pot rapid biosensing platform integrating turn-back loop primer-accelerated LAMP and Pyrococcus furiosus Argonaute for meat visual authentication. J Zhejiang Univ-Sci B, 27(7):775-787.

[5]GaoW, EmaminejadS, NyeinHYY, et al., 2016. Fully integrated wearable sensor arrays for multiplexed in situ perspiration analysis. Nature, 529(7587):509-514.

[6]GootenbergJS, AbudayyehOO, LeeJW, et al., 2017. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science, 356(6336):438-442.

[7]HeXB, QianXY, ZhengXG, et al., 2026. Selenocystine-based fluorescence assay combined with structural prediction for functional analysis of cystine transporter variants in cystinuria. J Zhejiang Univ-Sci B, 27(7):806-816.

[8]HuangY, YeJL, XuL, et al., 2026. Dual-functional nanoplatform for simultaneous degradation of circRNA CDR1as and real-time monitoring of miR-7 in live cells. J Zhejiang Univ-Sci B, 27(7):761-774.

[9]LiJ, ZhaoYF, MaYC, et al., 2026. Machine learning-driven evaluation of protein kinase D3 as a co-diagnostic biomarker in hepatocellular carcinoma. J Zhejiang Univ-Sci B, 27(7):788-805.

[10]LiX, ChenHL, WangX, et al., 2026. Advances in biomarkers for Parkinson’s disease: from molecular pathology to precision diagnostics. J Zhejiang Univ-Sci B, 27(7):736-760.

[11]LuoRP, TangZJ, DingMQ, et al., 2026. Programmable DNAzyme nanocatalysts for tumor immunometabolic modulation. J Zhejiang Univ-Sci B, 27(7):698-714.

[12]McConnellEM, CozmaI, MouQ, et al., 2021. Biosensing with DNAzymes. Chem Soc Rev, 50(16):8954-8994.

[13]MudanyaliO, DimitrovS, SikoraU, et al., 2012. Integrated rapid-diagnostic-test reader platform on a cellphone. Lab Chip, 12(15):2678-2686.

[14]OngaroAE, NdlovuZ, SollierE, et al., 2022. Engineering a sustainable future for point-of-care diagnostics and single-use microfluidic devices. Lab Chip, 22(17):3122-3137.

[15]ParnettiL, GaetaniL, EusebiP, et al., 2019. CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol, 18(6):573-586.

[16]PlebaniM, NicholsJH, LuppaPB, et al., 2025. Point-of-care testing: state-of-the art and perspectives. Clin Chem Lab Med, 63(1):35-51.

[17]Quesada-GonzálezD, MerkoçiA, 2015. Nanoparticle-based lateral flow biosensors. Biosens Bioelectron, 73:47-63.

[18]StavelinA, SandbergS, 2024. Analytical performance specifications and quality assurance of point-of-care testing in primary healthcare. Crit Rev Clin Lab Sci, 61(3):164-177.

[19]TopolEJ, 2019. High-performance medicine: the convergence of human and artificial intelligence. Nat Med, 25(1):44-56.

[20]VennerAA, BeachLA, SheaJL, et al., 2021. Quality assurance practices for point of care testing programs: recommendations by the Canadian Society of Clinical Chemists point of care testing interest group. Clin Biochem, 88:11-17.

[21]WangHM, ChenYQ, WangH, et al., 2019. DNAzyme-loaded metal-organic frameworks (MOFs) for self-sufficient gene therapy. Angew Chem Int Ed Engl, 58(22):7380-7384.

[22]WangMM, GanL, FanYR, et al., 2026. Blood‒brain barrier permeability assessment: from biomimetic models to multimodal imaging. J Zhejiang Univ-Sci B, 27(7):715-735.

[23]WangMQ, YangYR, MinJH, et al., 2022. A wearable electrochemical biosensor for the monitoring of metabolites and nutrients. Nat Biomed Eng, 6(11):1225-1235.

[24]WiensJ, SariaS, SendakM, et al., 2019. Do no harm: a roadmap for responsible machine learning for health care. Nat Med, 25(9):1337-1340.

[25]YetisenAK, AkramMS, LoweCR, 2013. Paper-based microfluidic point-of-care diagnostic devices. Lab Chip, 13(12):2210-2251.

[26]ZhangW, HangYD, ZhanSS, et al., 2026. Emerging point-of-care technologies for bacterial pathogen detection. J Zhejiang Univ-Sci B, 27(7):677-697.

Similar articles